International Association of
Therapeutic Drug Monitoring and Clinical Toxicology
Fostering education, research and practice in TDM and CT

Interview with Ryuji Kato (English)

Kato Ryuji 150x200

As we lead up to the 2017 Kyoto Congress, the IATDMCT Communications Committee is delighted to bring to you the July, August and September Blogs in both English and Japanese.  We are delighted to start this series with Ryuji Kato; former IATDMCT Young Scientist Committee member and current member of the IATDMCT Communications Committee.

 

Ryuji Kato
Department of Cardiovascular Pharmacotherapy and Toxicology
Osaka University of Pharmaceutical Sciences
Osaka, Japan

 

We look forward to seeing you all in Kyoto!

Interview with Ryuji Kato (Japanese)

Kato Ryuji 150x200

今秋開催される2017 Kyoto Congressに向けての企画として、IATDMCT Communications Committeeでは、7、8、9月のBlogを日本語と英語でお届けします。7月は加藤隆児先生(前 IATDMCT Young Scientist Committee member、現IATDMCT Communications Committee member)です。

 

加藤隆児
大阪薬科大学循環病態治療学研究室

 

京都でお会い出来ることを楽しみにしています!

Spotlight on the June 2017 Compass

IATDMCT2017 Kyoto logo gold

THE 15th IATDMCT CONGRESS: Expansion and Evolution of TDM/CT
This month we are bringing to you an article from the June 2017 Compass which provides an exciting overview on the upcoming IATDMCT 2017 Congress, Kyoto, Japan.  It highlights important dates, registration information, scientific program details, social events and the planned Young Scientists activities.

Yamamoto 150x200Tanigawara Yusuke 150x200

 

We look forward to seeing you all in Kyoto!

 

Many thanks to Organisers for this article:
Yusuke Tanigawara (Congress Chair, right
Takehito Yamamoto (IATDMCT YS Committee member), far right)

Spotlight on the March 2017 Compass

compass logo trans round

The IATDMCT Congress is fast approaching, and the March 2017 Compass opens with a useful overview of practical information for members.  Scientific reports include the current state of Vancomycin TDM, which despite more than five decades of clinical application, continues to pose challenges: novel approaches are being refined for clinical use. We revisit medicinal use of cannabis, this time from the perspective of the Toxicology Committee, and we hear about laboratory assays aimed at determining idiosyncratic, Type B, adverse drug reactions.  Finally, our German colleagues share details about a special event held to celebrate the retirement of Hans Maurer, IATDMCT past-president, who took his bow with a presentation about potions and poisons in opera and the arts: well worth a read.

 

Many thanks to the Compass Editorial Team:

Paula Schaiquevich
Edgar Spencer
Franck Saint-Marcoux

Page 1 of 9

The content of the IATDMCT Blog does not necessarily have the endorsement of the Association.